Alkermes, Plc (ALKS)
by Zacks Equity ResearchJuly 11, 2012 | Comments : 0 Recommended this article: (0)
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at email@example.com or call 800-767-3771 ext. 9339.
The expanded portfolio caused the company to provide bright revenue guidance for fiscal 2013. We believe that Alkermes will achieve the guidance. We are also impressed by the FDA approval and launch of diabetes drug, Bydureon, which offers significant commercial potential.
We are also pleased by the pipeline progress at Alkermes. We believe that there is significant scope for stock price appreciation from current levels.
Please login to Zacks.com or register to post a comment.